|1.||Sukumar, Saraswati: 8 articles (05/2011 - 05/2003)|
|2.||Fackler, Mary Jo: 7 articles (05/2011 - 11/2003)|
|3.||Schimmer, Aaron D: 5 articles (04/2011 - 12/2007)|
|4.||Mao, Xinliang: 5 articles (04/2011 - 12/2007)|
|5.||Argani, Pedram: 5 articles (09/2008 - 12/2003)|
|6.||Hurren, Rose: 4 articles (04/2011 - 12/2007)|
|7.||Campo, Elias: 4 articles (11/2009 - 02/2004)|
|8.||Trudel, Suzanne: 3 articles (04/2011 - 12/2007)|
|9.||Datti, Alessandro: 3 articles (02/2011 - 12/2007)|
|10.||Rosenwald, Andreas: 3 articles (11/2009 - 02/2004)|
10/15/2010 - "Moreover, cyclin D2 dramatically reduced tumor growth and development in Apc(Min/+) mice. "
04/19/2012 - "Molecular studies identified a marked attenuation of the PI3K-AKT-β-catenin signaling pathway that led to decreased protein levels of cyclin D2, thereby decreasing tumor cell proliferation in Thrb(PV/PV)-PTU mice. "
10/01/2003 - "To study the cell cycle-regulatory factors involved in ovarian, testicular, and adrenal tumor development in vivo, we have bred Inhalpha mutant mice to mice with targeted disruptions of the p27 and cyclin D2 genes. "
01/01/2015 - "Cyclin D2 is implicated in tumor suppression. "
05/01/2013 - "Altogether, our results confirm that VPA is an anticancer therapeutic drug for the treatment of tumors with epigenetically repressed cyclin D2 expression."
|2.||Breast Neoplasms (Breast Cancer)
01/01/2015 - "In our study, we carried out the MSP assay to evaluation the methylation status at CpG islands in the cyclin D2 promoter in breast cancer cases from the Vietnamese population. "
01/01/2015 - "Our results confirmed the cyclin D2 hypermethylation could be used as the potential biomarker which could be applied in prognosis and early diagnosis of Vietnamese breast cancer patients. "
01/01/2015 - "Loss of expression of cyclin d2 by aberrant DNA methylation: a potential biomarker in vietnamese breast cancer patients."
08/01/2008 - "A long-term follow-up study based on a quantitative evaluation of cyclin D2 and RARbeta2 methylation in cirDNA will provide the data on applicability of these markers for breast tumor predictive diagnostics."
08/01/2008 - "The applicability of cyclin D2 and RARbeta2 methylated markers for the development of a breast tumor screening assay was evaluated. "
01/01/2012 - "Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations."
03/17/2011 - "Dysregulation of cyclin D2 contributes to the pathogenesis of multiple myeloma, and can occur through translocations that activate MAF/MAFB or MMSET/FGFR3. "
12/01/2007 - "The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. "
11/01/2007 - "The oncogene c-Maf was recently found to be overexpressed in approximately 50% of multiple myeloma cases, and a role for c-Maf in promoting cyclin D2 expression has been postulated. "
04/01/2011 - "Therefore, we found that amitriptyline inhibited cyclin D2 transactivation and HDAC activity and could be a promising treatment for multiple myeloma."
09/01/2006 - "Further, hypoxia-exposed pulp cells showed improvement of cell viability, cell-cycle progression, and expression of cyclin D2 with re-oxygenation. "
01/01/2015 - "Furthermore, the expression of cyclin D2 was significantly decreased due to anoxia, while p27 expression was increased. "
04/15/2013 - "In both fetal hearts and H9c2 cells, hypoxia resulted in a significant decrease in a cell division marker cyclin D2 but an increase in a cell division inhibitor p27. "
09/01/2006 - "These findings indicate that hypoxia-induced cell cycle arrest in pulp cells is reversible, while cyclin D2 may play an essential role in the improvement of cell proliferation with re-oxygenation."
04/15/2013 - "Knockdown of TIMP-3 in H9c2 cells significantly increased cyclin D2 and Ki-67 and partially blocked the hypoxia-induced inhibition of cyclin D2 and Ki-67 in H9c2 cells. "
|5.||Prostatic Neoplasms (Prostate Cancer)
05/30/2015 - "SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3."
01/01/2011 - "Our results demonstrated the ability of SFN to epigenetically modulate cyclin D2 expression, and provide novel insights into the mechanisms by which SFN may regulate gene expression as a prostate cancer chemopreventive agent."
01/01/2011 - "Promoter hyper-methylation of cyclin D2, a major regulator of cell cycle, is correlated with prostate cancer progression, and restoration of cyclin D2 expression exerts anti-proliferative effects on LnCap prostate cancer cells. "
09/11/2009 - "Despite well known oncogenic function of G1-S cell-cycle progression, cyclin D2 (CCND2) is often silenced epigenetically in prostate cancers. "
12/01/2003 - "Finally, we identified a few genes such as cyclin D2, p19ink4d, and Fas that are directly regulated by Egr-1 in prostate cancer cells and that control cell cycle and survival."
|1.||DNA (Deoxyribonucleic Acid)
|5.||gamma Catenin (Plakoglobin)
|10.||Tumor Suppressor Protein p14ARF (p14ARF)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Stem Cell Transplantation
|3.||Prostatectomy (Retropubic Prostatectomy)
|4.||Drug Therapy (Chemotherapy)